On February 22, 2023 Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company") a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, reported that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in two upcoming investor conferences in March 2023 (Press release, Beyond Air, FEB 22, 2023, View Source [SID1234627530]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

35th Annual Roth Conference – March 12-14, 2023
Format: Fireside Chat
Date: Monday, March 13, 2023
Participant: Steve Lisi, Chairman & CEO, Beyond Air
Location: Laguna Niguel, CA
Oppenheimer 33rd Annual Healthcare Conference – March 13-15, 2023
Format: Presentation
Date & Time: Wednesday, March 15, 2023, at 9:20-9:50 AM ET
Participant: Steve Lisi, Chairman & CEO, Beyond Air
Location: Virtual presentation
Webcast Link: Click Here
Please contact your representative at either Roth or Oppenheimer to schedule a one-on-one meeting with Beyond Air during the respective conference.